Introduction
============

Statins are first-line drugs for treating hypercholesterolemia and used for primary and secondary CVD prevention. However, with the increasing clinical application of statins, accumulated evidence from clinical trials suggests that statins can increase the risk of new-onset DM, but the underlying pathological mechanism remains to be determined ([@B7]). Statins are 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase (HMG-CoA reductase) inhibitors, which were first approved for clinical use by the FDA in 1987. In addition to inhibiting cellular cholesterol synthesis, statins also up-regulate the LDLR in the liver and peripheral tissues, resulting in increased blood LDL-C removal and reduced CVD risk ([@B4]). However, the following great mystery remains: why do statins reduce blood cholesterol but also cause T2DM? After all, hypercholesterolemia is also an important risk factor for T2DM.

Previous studies suggest that statins also act by inhibiting glucose transporter 4, isoprenoid, Coenzyme Q10, Dolichol Biosynthesis and other mechanisms to cause insulin resistance and diminished insulin secretion in patients ([@B4]; [@B3]; [@B7]). Nevertheless, these findings usually depend on the investigation of individual statins, and the mechanism underlying the general diabetogenic effect of statins is unknown. More importantly, these studies do not address whether cholesterol metabolism is involved with the diabetogenic effect of statins, even though the main pharmacological effect of statins is to decrease blood cholesterol.

Fortunately, a serial of studies based on a population with FH have shed light on these questions ([@B36]). FH patients were reported to present a relatively low incidence of DM in contrast to their unaffected relatives or hyperlipidemic patients, even when these patients were subjected to intensive statin treatment ([@B6]). Since most FH patients in these studies have heterozygous mutation in the LDLR gene, an interesting question arises as to whether LDLR mediated cellular cholesterol metabolism is involved with the diabetogenic effect of statins ([@B24]; [@B5]). Indeed, dysregulation of cellular cholesterol metabolism severely impairs the function of pancreatic β cells, as has been shown by *in vitro* and *in vivo* studies ([@B9]). Moreover, in a mouse model lacking the LDLR, the pancreatic β cells are protected from accumulation of cholesterol and cholesterol-induced β cell dysfunction, whereas mice carrying more LDLR exhibit pancreatic islet abnormalities ([@B18]; [@B22]). Overall, these novel findings lead us to speculate that LDLR-mediated cellular cholesterol metabolism may associate with the diabetogenic effect of statins.

Association between Stains Intake and the Risk of New-Onset T2DM
================================================================

The association between statin treatment and the prevalence of T2DM has been examined extensively. This association was first reported by [@B27], with their data suggesting that rosuvastatin had a higher incidence of physician-reported DM. A meta-analysis with 91140 participants covering 13 statins showed that statin therapy was associated with a 9% increased risk for incident DM ([@B30]). In the SPARCL trial, a population with statin treatment had an 11% higher risk of DM than the placebo group. Moreover, Culver et al. reported a 48% increase in the risk of new-onset DM among women prescribed a statin, after adjusting for potential confounding factors ([@B12]). Similarly, a population-based study showed that treatment with higher atorvastatin, simvastatin or rosuvastatin doses was associated with an increased risk for new-onset DM (22, 10, and 18%, respectively) ([@B10]). A recent study concluded that statin users were more commonly diagnosed with DM and diabetic complications even after adjustment for potential confounding factors during the follow-up period ([@B21]). In regards to these numerous clinical trials and meta-analyses, the data strongly support statins modestly increasing the risk for DM ([@B31]). Nevertheless, it is important to note that statins are highly effective for prevention of cardiovascular events in individuals with or without DM ([@B3]). The Cholesterol Treatment Trialist investigators concluded that the net absolute benefit observed with statin therapy in such individuals is more than 50 times larger than any putative effect on DM ([@B16]). As a result of clinical observations, numerous studies suggest that statins are irreplaceable for the prevention and treatment of CVD ([@B3]). In view of the fact that statins have a very important role in the primary and secondary prevention of CVD, the underlying mechanism that are responsible for the diabetogenic effect of statins and novel strategies for reducing the side effects should therefore be explored.

Inverse Association of FH and the Risk of T2DM
==============================================

To our knowledge, the low risk of DM in FH patients was first reported in 1997 by [@B35]. They found that the prevalence of DM was higher in the non-FH group, reaching 18.7% compared with 3.9% in the FH patients with a defective allele at LDLR and 7.9% in FH patients with a null mutation at LDLR (**Table [1](#T1){ref-type="table"}**) ([@B35]). This phenomenon was confirmed by another cross-sectional study, showing that familial combined hyperlipidaemia (FCH) patients had a significantly increased prevalence of DM (13%) vs an FH group with LDLR mutations (2%) (**Table [1](#T1){ref-type="table"}**) ([@B32]). [@B33] presented a study regarding the role of long duration statin treatment on DM incidence of FH patients with LDLR mutations, reporting that 14% of FCH and only 1% of FH patients developed DM during follow-up (**Table [1](#T1){ref-type="table"}**). They also concluded that long duration of high statin treatment did not seem to be associated with diabetic risk in FH patients. These results were confirmed by other studies (**Table [1](#T1){ref-type="table"}**) ([@B19]; [@B15]). A recent cross-sectional study may provide some novel insights into the inverse association between FH and prevalence of DM (**Table [1](#T1){ref-type="table"}**) ([@B6]). Data from this study suggested that the prevalence of T2DM in FH patients was 50% lower than that in unaffected relatives despite these FH patients showing greater statins use. Interestingly, they observed an inverse relationship between the severity of the FH causing mutation and the prevalence of T2DM, indicating that patients with LDLR-negative mutations have the lowest prevalence of T2DM. Taking these results together, a novel phenomenon is raised, whereby FH patients with LDLR mutations may be protected against T2DM and the diabetogenic effect of statins.

###### 

Summary of population studies investigating onset of DM in FH patients with statins treatment.

  Author and Published year   Country      Study design                                   Population and the cause of FH                                                                                                                                DM-related findings
  --------------------------- ------------ ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B35]                      Canada       Case control study                             102 patients without FH, 102 hFH patients; a defective allele at LDLR or LDLR mutation.                                                                       The prevalence of DM was significantly higher in the non-FH group than in the two FH groups (*P* \< 0.05).
  [@B32]                      Greece       Cross-sectional study.                         A total 1306 subjects: 600 individuals with hFH, and 706 individuals with FCH; LDLR mutation or plasma levels of LDL cholesterol above the 95th percentile.   FCH had a significantly increased prevalence of DM (13 vs. 2%, *P* \< 0.001) vs FH group, whereas total cholesterol, LDL-cholesterol, and apolipoprotein B levels were higher (all *P* \< 0.001) in FH subjects.
  [@B33]                      Greece       Ambispective cohort study.                     A total of 523 adult patients (314 hFH and 209 FCH patients); LDL-receptor mutation or plasma levels of LDL cholesterol above the 95th percentile.            14% of FCH and only 1% of hFH patients developed DM during follow up.
  [@B19]                      Netherland   Retrospective cohort study                     2144 children with hFH; LDR mutation.                                                                                                                         Statin treatment was not associated with an increased risk of new-onset DM in these patients.
  [@B6]                       Netherland   Cross-sectional study                          All individuals (*n* = 63 320) who underwent DNA testing for FH; 3475 were ApoB mutation carriers, 21 606 had the LDLR mutation, and 56 had PCSK9 mutation.   The prevalence of T2DM was 1.75% in FH patients (*n* = 440/25 137) vs 2.93% in unaffected relatives (*P* \< 0.001). The adjusted prevalence of type 2 DM by APOB vs LDL receptor gene was 1.91% vs 1.33%.
  [@B15]                      Spain        Cross-sectional and prospective cohort study   2558 FH and 1265 unaffected relatives with a mean follow-up of 5.9 years; LDLR mutation.                                                                      Finally, in the adjusted Kaplan--Meier curve, there are no differences between FH group vs control group in the incidence of T2DM according the duration of treatment with statins.

hFH, heterozygous Familial Hypercholesterolemia; FCH, familial combined hyperlipidemia; LDLR, low density lipoprotein receptor; T2DM, type 2 diabetes mellitus; PCSK9, proprotein convertase subtilisin/kexin type 9; ApoB, apolipoprotein B

.

Regulation of LDLR Expression by Statins
========================================

As mentioned above, there are two ways of that statins reduce the blood cholesterol: by inhibited HMG-CoA reductase, statins can efficiently reduce formation of LDL-C in blood; additionally, statins also up-regulate LDL receptor in liver and peripheral tissues, resulting in increased blood LDL-C removal ([@B4]). Of a pathway in the regulation of LDLR, statins can cause up-regulation of sterol regulatory element-binding protein 2 (SREBP-2) in hepatocytes (**Figure [1](#F1){ref-type="fig"}**). SREBP-2 is known as a transcription factor, which efficiently stimulates transcription of LDLR and other sterol-regulated genes (**Figure [1](#F1){ref-type="fig"}**) ([@B8]). As a result of statin incubation, LDLR and its mRNA levels are raised in Hep G2, human and rat hepatocytes ([@B25]). In statin-treated dogs, they usually show increased hepatic LDLR as previously reported ([@B1]). Nevertheless, LDLR expression in statins-treated animals also is not extremely high, because LDLR is subjected to negative feedback regulations as well (**Figure [1](#F1){ref-type="fig"}**). On the one hand, cellular cholesterol accumulation may lead to increased oxysterols, which are the natural ligands for liver X receptor (LXR). Activation of LXR can positively regulate transcription of inducible degrader of the LDLR (Idol, a ubiquitin ligase) to degrade the LDLR (**Figure [1](#F1){ref-type="fig"}**) ([@B17]). On the other hand, SREBP-2 also up-regulates PCSK9 in liver, which is a powerful enzyme to mediate the degradation of LDLR (**Figure [1](#F1){ref-type="fig"}**) ([@B26]). In contrast to liver, the regulation of LDLR in pancreatic islets has not been fully elucidated. If LDLR expression in pancreatic islets is subjected to similar regulations as shown in liver, there is an interesting question whether negative feedback regulation is affected in statins-treated patients with the pathological condition.

![A schematic diagram representing the regulation of hepatic LDLR by statins. (1) Statins up-regulate LDLR via SREBP2. (2) SREBP2 also increases transcription of PCSK9 to degrade LDLR. (3) Cellular cholesterol accumulation may activate LXR, which up-regulates Idol to degrade LDLR.](fphar-08-00372-g001){#F1}

Lipid-Lowering Therapy, LDLR and Dysfunction of Pancreatic Islets
=================================================================

Hyperlipidaemia increases the risk for both CVD and T2DM, suggesting that lipid-lowering drugs for treating CVD may also have protective effects on pancreatic islets and thus prevent the onset of T2DM. For instance, bezafibrate that is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia, is also proven that can reduce the incidence and delay the onset of T2DM in high risk patients ([@B34]). In addition, patients received ezetimibe and colesevelam for treating dyslipidaemia might also be shown to decrease the risk of the onset of T2DM ([@B2]). In animal model, statins had some beneficial effects on pancreatic islets, e.g., atorvastatin preserved pancreatic β cell function in obese C57BL/6 J mice ([@B11]), and pitavastatin suppressed high fat diet (HFD)-induced the pathogenesis of pancreatic islets in rats ([@B23]). However, it is well known that statins lower LDL cholesterol, while they have negative effects on pancreatic islets. The molecular mechanisms behind this side effect involve with an increased LDLR-mediated uptake of LDL-C in islets via statins-induced up-regulation of the LDLR expression. Most likely, there is a potential mechanism that the pancreatic islets are impaired by abnormal cholesterol levels via the up-regulation of LDLR expression and subsequent increased LDLR-mediated uptake of LDL-C. Thus, LDLR mutation in patients with FH may prevent the onset of T2DM as well as the diabetogenic effect of statins. Indeed, numerous studies have revealed that the accumulation of cholesterol in the pancreatic islets leads to dysfunction of pancreatic β cell ([@B9]; [@B14]). *In vitro*, the addition of LDL-C to rat islet β cells results in cell death in an LDLR-depended manner ([@B28]), while the inhibitory effect of LDL on insulin secretion can be abolished by LDLR deficiency ([@B29]). Furthermore, increased LDLR may allow more modified LDL-C entering islet β cells and finally causes cytotoxicity to these cells. *In-vivo* studies provide further evidences that the LDLR may play a key role in islet function ([@B31]). Using the LDLR-deficient mouse, [@B18] have found that lack of LDLR protects pancreatic β cells from the accumulation of cholesterol and cholesterol-induced β cell dysfunction. Furthermore, PCSK9-null male mice with more LDLR in pancreatic islet β cells exhibit impaired glucose tolerance and pancreatic islet abnormalities ([@B22]). Similarly, variations in PCSK9 and HMGCR are associated with nearly identical protective effects on the risk of cardiovascular events but are also associated with very similar effects on the risk of DM ([@B13]). Not only the above two genes, LDL-C-lowering genetic variants in a number of genes are found that are associated with a higher risk of T2DM, which may further confirm the potential adverse effects of LDL-C-lowering therapy ([@B20]). Combined with the FH studies, these results strongly support a model whereby LDLR-mediated uptake of LDL-C and cellular cholesterol accumulation is the pathological basis for the prevalence of T2DM and the diabetogenic effects of statins.

Conclusion
==========

The common pathway in FH and statin-induced DM is LDLR-mediated uptake of LDL-C, and elucidation of this pathway may help us to understand the potential mechanism for the diabetogenic effects of statins. Moreover, this pathway closely associates with the pharmacological effect of statins but is independent of the type of statin. If this pathway is proven, we can not only utilize it to prevent the diabetogenic effects of statins but can also target this pathway to treat T2DM.
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CVD

:   cardiovascular disease

DM

:   diabetes mellitus

FCH

:   familial combined hyperlipidemia

FH

:   familial hypercholesterolemia

LDL-C

:   low density lipoprotein-cholesterol

LDLR

:   low-density lipoprotein receptor

PCSK9

:   proprotein convertase subtilisin/kexin type 9

T2DM

:   type 2 diabetes mellitus.
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